![Healing Nation Cbd Gummies: A Practical Look At Their Role In Daily Wellness [mlPjEnTxkY4]](https://i0.wp.com/cedclinic.com/wp-content/uploads/2026/08/ced-pexels-6693918.jpg?resize=150%2C150&ssl=1 "Healing Nation Cbd Gummies: A Practical Look At Their Role In Daily Wellness [mlPjEnTxkY4] 26")
![Strawberry Cbd Gummies: A Practical Look At Taste, Effects, And Everyday Use [AsDivurPsHj]](https://i0.wp.com/cedclinic.com/wp-content/uploads/2026/08/ced-pexels-9743242.jpg?resize=150%2C150&ssl=1 "Strawberry Cbd Gummies: A Practical Look At Taste, Effects, And Everyday Use [AsDivurPsHj] 29")
Efficacy and safety of GLP-1 receptor agonists in Parkinson’s disease- a systematic review
A recent study examines the use of GLP-1RAs in Parkinson's disease, finding no significant motor benefits but some improvement in quality of life.
Ethical Issues Related to the Use of GLP‐1 Receptor Agonists Such as Ozempic and Wegovy and Monjaro
GLP-1 receptor agonists offer significant health benefits but raise ethical concerns about long-term safety, access equity, and societal impacts.
GLP-1 agonists in addiction therapy – review
GLP-1 receptor agonists show promise in reducing alcohol consumption and cravings, as well as supporting nicotine abstinence. However, more research is needed for stimulant use disorders.
Safety of GLP-1 receptor agonists in body contouring surgery- a systematic review
A systematic review found a possible but fragile signal for increased wound dehiscence with GLP-1 RA use in body contouring. No other significant perioperative complications were observed.
SemaGBA- A System Dynamics Model of the Semaglutide-Responsive Gut-Brain Axis
The SemaGBA model simulates semaglutide's effects on metabolic and neural pathways, providing insights into its mechanisms of action.
Short-term effect of tirzepatide on serum calcitonin in adults with obesity
Tirzepatide treatment for 12 weeks resulted in a modest increase in serum calcitonin levels, remaining within normal ranges and showing no clinically relevant thyroid abnormalities.
GLP-1 RAs and Kidney Cancer Risk- Methodological Considerations in Active-Compara
A recent study using target trial emulation found no increased kidney cancer risk with GLP-1 RAs compared to SGLT2 inhibitors, challenging prior findings.
GLP-1 Receptor Agonists and NAION
GLP-1 receptor agonists likely increase NAION risk approximately twofold, but this rare event does not outweigh their cardiovascular and metabolic benefits for most patients.
GLP-1 Receptor Agonists as a Novel Solution for Antipsychotic-Induced Weight Gain
GLP-1RAs show promise in reducing antipsychotic-induced weight gain without worsening psychiatric symptoms, offering a new approach for SPMI patients.
GLP-1 receptor agonists in patients with cancer are associated with reduced all-cause mortality
GLP-1 receptor agonists are associated with a statistically significant reduction in all-cause mortality for cancer patients with type 2 diabetes. This study highlights the potential benefits of GLP-1RAs in oncology settings.